PreprintBrief ReportVersion 1This version is not peer-reviewed
Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up
Version 1
: Received: 9 August 2024 / Approved: 12 August 2024 / Online: 12 August 2024 (12:36:39 CEST)
How to cite:
Lanzafame, M.; Lattuada, E.; Delama, A.; Mori, G.; Vento, S. Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. Preprints2024, 2024080746. https://doi.org/10.20944/preprints202408.0746.v1
Lanzafame, M.; Lattuada, E.; Delama, A.; Mori, G.; Vento, S. Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. Preprints 2024, 2024080746. https://doi.org/10.20944/preprints202408.0746.v1
Lanzafame, M.; Lattuada, E.; Delama, A.; Mori, G.; Vento, S. Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. Preprints2024, 2024080746. https://doi.org/10.20944/preprints202408.0746.v1
APA Style
Lanzafame, M., Lattuada, E., Delama, A., Mori, G., & Vento, S. (2024). Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. Preprints. https://doi.org/10.20944/preprints202408.0746.v1
Chicago/Turabian Style
Lanzafame, M., Giovanni Mori and Sandro Vento. 2024 "Short Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up" Preprints. https://doi.org/10.20944/preprints202408.0746.v1
Abstract
Short-cycle therapy has proven to be a safe and effective alternative to standard everyday antiretroviral treatment for virally suppressed people living with HIV. Here we report a favorable long-term virological and immunological outcome in 12 virally suppressed people on short cycle therapy with bictegravir/emtricitabine/tenofovir alafenamide administered five days a week (Monday to Friday).
Keywords
Antiretroviral treatment; short cycle therapy; HIV; virologically suppressed people; bictegravir
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
